App-Quantinova.ai

Real-life efficacy and safety of nivolumab for non-small cell lung cancer: A 10-months French cohort.

Jennifer Corny - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

Effect of molecular profile in non-small cell lung carcinoma on the development of brain metastases.

Sarah Turner - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

Ataxia in long term survivors of lung cancer after whole brain radiation therapy (WBRT).

Vivek Kumar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effects of FDA drug approvals on a thoracic oncology programs clinical trial enrollment in 2015.

Alice Huai-Yu Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Liver metastases and sensitivity to checkpoint inhibition in patients with non-small cell lung cancer (NSCLC).

Rathi Narayana Pillai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers.

Bob T. Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.

Elizabeth Iannotti Buchbinder - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Interleukin

Ulceration of primary cutaneous melanoma and the development of brain metastases: A retrospective chart review.

Veronica Rutt - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Topical immunotherapy with diphencyprone (DPCP) for in-transit and other melanoma cutaneous lesions: Canadian single-institution case series.

Carrie Yeung - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Diphenylcyclopropenone

Impact of aging on immune response and survival in melanoma.

Sarah Ann Weiss - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Acceptance of illness of advanced cancer patients in palliative care center in Kuwait.

Khalid Al Saleh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Experience with palliative sedation (PS) in an inpatient oncology setting.

Diogo Bugano Diniz Gomes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Midazolam

Room for improvement regarding patient involvement in decisions to limit treatment: Results from the EPAL-study (Ethics Policy for Advanced Care Planning and Limiting Treatment).

Eva Caroline Winkler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of palliative care (PC) on aggressive end-of-life (EOL) care indicators among advanced cancer patients (ACPs).

Carlos Eduardo Paiva - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A confirmatory survey regarding public misconception about cardiopulmonary resuscitation (CPR) in advanced cancer patients.

Santhanam Sundar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Influence of socioeconomic status and religious belief on palliative care in terminally ill cancer patient in a private hospital of central Nepal.

Shristi Tiwari - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Solid malignancies

N/A

The do-not-resuscitate order for terminal cancer patients in China mainland: A retrospective research.

Boyan Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Changing patterns of hospice and end of life care.

Jolyn Sharpe Taylor - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Patterns of intensity of end of life care for adolescents and young adults with cancer: A population based study.

Emily E. Johnston - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Geriatric oncology (GO) and education: Is the research community really involved in presenting data about elderly and learning in cancer?

Aldo A. Dettino - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts